Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy

Obstetrics and Gynecology

Volumn 91, Issue 5, 1998, Pages 678-684

  Nand, Swaran L ^a,b,c   Webster, Michael A ^a,b,c   Baber, Rodney ^a,b,c   O'connor, Vivienne ^a,b,c  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; PIPERAZINE ESTRONE SULFATE;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VAGINA BLEEDING;

ADULT; BIOPSY, NEEDLE; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; UTERINE HEMORRHAGE;

EID: 0031970090     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1080/00006250-199805000-00007     Document Type: Article

References (21)

1. Hammond CB. Menopause and hormone replacement therapy: An overview. Obstet Gynecol 1996;87:2-15.
2. Stampfer MJ, Colditz GA. Oestrogen replacement therapy and coronary artery disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
3. Barrett-Connor E, Bush TL. Estrogens and coronary heart disease in women. JAMA 1991;265:1861-7.
4. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
5. Ziel HK, Finkle WD. Increased risk of endometrial cancer among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
6. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
7. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
8. Grambell RD Jr. Prevention of endometrial cancer with progesto-gens. Maturitas 1986;8:159-68.
9. Persson I, Adami HO, Bergkvist L, Lindgren A, Patterson B, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens. Results of a prospective study. BMJ 1989;298:147-51.
10. Lind T, Cameron EC, Hunter WM, Leon C, Moran PF, Oxley A, et al. A prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol 1979;86(suppl):1-29.
11. Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progesterone therapy in postmenopausal women. Obstet Gynecol 1985;65:469-99.
12. Weinstein L, Bewtra C, Gallagher JC. Evaluation of continuous low dose regime of estrogen progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990;162:1534-42.
13. Archer DF, Pikar JH, Bottiglioni F. Bleeding pattern in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogen with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-92.
14. Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M. Effect of estrone sulphate on postmenopausal bone loss. Obstet Gynecol 1990;76:579-84.
15. MacLennan AH, MacLennan A, Wilson D. The prevalence of oestrogen replacement therapy in South Australia. Maturitas 1993; 16:175-83.
16. MacLennan AH, Taylor AW, Wilson DH. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995;162:420-2.
17. Hahn R. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161:1854-8.
18. Whitehead MI, Townsend PT, Pryce-Davies J, Ryder TA, King JB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-605.
19. Sturdee DW, Barlow DH, Ulrich LG, Wells M, Gydesen H, Campbell M. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? Lancet 1994;344:979-82.
20. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349: 458-61.
21. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and post menopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997;176:377-80.